Back

Do we need a new P2Y12 receptor antagonist?

European Heart Journal

17 December 2019
Organised by: Logo
Read full article
ESC Journals CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE Acute Coronary Syndromes VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE Myocardial Disease

Abstract

Abstract

Contributors

Jean-Sébastien Hulot
Jean-Sébastien Hulot

Author

Gilles Montalescot
Gilles Montalescot

Author

Sorbonne University Paris , France

You may be interested in
thumbnail
Congress Presentation
Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients
1 September 2019
thumbnail
Congress Session
The new frontier in oral anticoagulation: Factor XIa inhibitors
16 April 2023
thumbnail
Congress Presentation
Impact of potent P2Y12 inhibitors in adverse events reduction in diabetic patients with Acute Coronary Syndromes. An analysis from ACHILLES Registry.
2 September 2019
thumbnail
Congress Presentation
Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources